Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trelagliptin vs Vildagliptin in T2DM
NCT06889909Active, not recruiting
- Sponsor
- Lahore General Hospital
- Start
- Dec 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of trelagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Lahore General Hospital. Primary endpoint: Percentage of Participants Achieving HbA1c <7% at 3 months. Started Dec 2024; status: active, not recruiting.
02
Drugs
trelagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06889909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06889909.